A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

With studies showing potential for SGLT2 inhibitors in heart failure ... to consider its product’s role for heart failure patients who do not have diabetes. Heart failure is estimated to ...

“These findings reinforce the use of dapagliflozin 10 mg, or other SGLT2 inhibitors, when the therapeutic goal is to reduce the risk of heart failure,” write HoJin ... which observational studies do ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

Diabetes statistics include: CKD statistics include: SGLT2 inhibitors work by blocking the kidneys ... in individuals who have conditions like heart failure, kidney disease, or heart disease.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is administered to reduce morbidity and mortality. Limited access to ...

The effects of SGLT2 inhibitors on ... These work indirectly in the heart by improving cardiorenal hemodynamics and reducing fibrosis. These drugs do not address the underlying cause of metabolic ...

In common with other complex diseases like heart failure ... an SGLT2 therapy. In it favour also is that it does not work as a diabetes medicine like the SGLT2s, so patiens on insulin do not ...